Lupin Reports 88% Jump in Q4FY26 Profit; Announces Rs 18 Dividend Amid Strong FY26 Growth

The Indian equity markets opened lower on Friday, with the benchmark Nifty 50 index trading down 0.47 per cent at 24,213.45 during the session. Despite weakness in frontline indices, stock-specific action remained visible in select pharmaceutical counters after quarterly earnings announcements. In this segment, Lupin remained in focus after the company reported its Q4FY26 and FY26 consolidated financial results along with a Dividend recommendation. However, Lupin's share price traded lower by 0.94 per cent at Rs 2,436.90 on Friday.

Lupin Q4FY26 Results

Lupin reported consolidated revenue from operations of Rs 7,474.66 crore in Q4FY26 as against Rs 5,667.13 crore in Q4FY25, registering a growth of 31.9 per cent YoY. Total income stood at Rs 7,615.37 crore during the quarter compared with Rs 5,724.08 crore reported in the corresponding quarter previous year.

Profit before Tax came in at Rs 1,928.00 crore in Q4FY26 as against Rs 895.84 crore reported in Q4FY25, marking a growth of 115.2 per cent YoY. Profit after tax for the quarter stood at Rs 1,413.07 crore compared with Rs 752.64 crore in the year-ago quarter, reflecting a growth of 87.8 per cent YoY. Basic earnings per share stood at Rs 31.96 as against Rs 16.93 reported in Q4FY25.

Lupin FY26 Annual Performance

For the financial year ended March 31, 2026, Lupin reported consolidated revenue from operations of Rs 27,958.03 crore as against Rs 22,707.90 crore in FY25, registering a growth of 23.1 per cent YoY. Total income for FY26 stood at Rs 28,382.48 crore compared with Rs 22,903.72 crore in the previous financial year.

Profit before tax stood at Rs 6,872.55 crore in FY26 compared with Rs 4,015.00 crore in FY25, marking a growth of 71.2 per cent YoY. Profit after tax came in at Rs 5,182.89 crore as against Rs 3,183.74 crore in FY25, reflecting a growth of 62.8 per cent YoY. Annual basic earnings per share stood at Rs 116.75 compared with Rs 71.95 in the previous financial year.

Dividend and Key Developments

The Board of Directors recommended a final dividend of Rs 18 per equity share of face value Rs 2 each for FY26, subject to shareholder approval at the upcoming Annual General Meeting.

During FY26, the company completed strategic business restructuring initiatives, including the transfer of OTC and API R&D businesses to wholly owned subsidiaries. Lupin also announced acquisitions including VISUfarma B.V. through Nanomi B.V. and Renascience Pharma Limited in the UK to strengthen its international presence.

Balance Sheet Highlights

On the balance sheet front, consolidated total assets increased to Rs 38,364.83 crore as on March 31, 2026 from Rs 29,204.88 crore a year ago. Total equity stood at Rs 22,513.37 crore compared with Rs 17,294.35 crore in FY25, while cash and cash equivalents increased sharply to Rs 4,167.73 crore.

About Lupin 

Lupin Ltd is one of India’s leading global pharmaceutical companies engaged in the development, manufacturing and marketing of branded and generic formulations, biotechnology products and active pharmaceutical ingredients. The company has a strong presence across therapeutic segments including cardiovascular, diabetes, respiratory, anti-infectives and central nervous system therapies.

The company operates manufacturing and research facilities across India and international markets, with a significant presence in the United States, Europe, Australia, South Africa and emerging markets. Lupin continues to focus on specialty products, complex generics and biosimilars to drive long-term growth.

Share your thoughts on Lupin’s Q4FY26 performance in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.